{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"13.0","value":"7.1"},{"groupId":"OG001","lowerLimit":"5.4","upperLimit":"15.3","value":"15.3"},{"groupId":"OG002","lowerLimit":"3.0","upperLimit":"14.5","value":"9.2"},{"groupId":"OG003","lowerLimit":"2.7","upperLimit":"16.6","value":"7.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"59"}],"units":"Participants"}],"description":"The time interval between the date of initial documentation of a response (PR or better) and the date of first documented evidence of progressive disease, death, or date of censoring for the subjects who had not progressed/died. The censoring date was the last adequate tumor assessment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ibrutinib PO 560 mg + Carfilzomib IV 20/27 mg/m2\n\nIbrutinib\n\nCarfilzomib","id":"OG000","title":"Cohort 1 (560 mg)"},{"description":"Ibrutinib PO 560 mg + Carfilzomib IV 20/36 mg/m2\n\nIbrutinib\n\nCarfilzomib","id":"OG001","title":"Cohort 2a (560 mg)"},{"description":"Ibrutinib PO 560 mg+ Carfilzomib IV 20/36 mg/m2 Dexamethasone PO 20 mg\n\nIbrutinib\n\nCarfilzomib\n\nDexamethasone","id":"OG002","title":"Cohort 2b (560 mg)"},{"description":"Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg\n\nIbrutinib\n\nCarfilzomib\n\nDexamethasone","id":"OG003","title":"All RP2D (840 mg)"}],"paramType":"MEDIAN","populationDescription":"Please note that the analysis only includes participants who achieved the best response of complete response or partial response from the All-treated population (per protocol).","reportingStatus":"POSTED","timeFrame":"Up to 4 years","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}